0000899243-23-000965.txt : 20230105
0000899243-23-000965.hdr.sgml : 20230105
20230105160553
ACCESSION NUMBER: 0000899243-23-000965
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NEUMANN CLARKE
CENTRAL INDEX KEY: 0001321466
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39334
FILM NUMBER: 23511287
MAIL ADDRESS:
STREET 1: 3595 JOHN HOPKINS CT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER NAME:
FORMER CONFORMED NAME: Neumann Clarke
DATE OF NAME CHANGE: 20050323
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001580063
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 273950390
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4330 LA JOLLA VILLAGE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92122
BUSINESS PHONE: 855-293-2639
MAIL ADDRESS:
STREET 1: 4330 LA JOLLA VILLAGE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92122
FORMER COMPANY:
FORMER CONFORMED NAME: PROGENITY, INC.
DATE OF NAME CHANGE: 20150617
FORMER COMPANY:
FORMER CONFORMED NAME: ASCENDANT MDX, INC.
DATE OF NAME CHANGE: 20130625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-03
0
0001580063
BIORA THERAPEUTICS, INC.
BIOR
0001321466
NEUMANN CLARKE
C/O BIORA THERAPEUTICS, INC.
4330 LA JOLLA VILLAGE DRIVE, SUITE 300
SAN DIEGO
CA
92122
0
1
0
0
See Remarks
Series X Preferred Stock
2023-01-03
4
D
0
44
D
0
D
On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company.
On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock.
Senior Vice President, General Counsel and Secretary
/s/ Will Pridgen, Attorney-in-Fact for Clarke Neumann
2023-01-05